The prognostic value of toll-like receptor5 and programmed cell death-ligand1 in patients with peripheral T-cell non-Hodgkin lymphoma

References

• Ellin F, Landstrom J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Blood. 2014;124:1570–1577.
   PubMed Web of Science ®Google Scholar
• Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26:4124–4130.
   PubMed Web of Science ®Google Scholar
• Casulo C, O'Connor O, Shustov A, et al. T-cell lymphoma: recent advances in characterization and new opportunities for treatment. J Natl Cancer Inst. 2017;109:djw248.
   PubMedGoogle Scholar
• Barton GM, Medzhitov R. Toll-like receptors and their ligands. Curr Top Microbiol Immunol. 2002;270:81–92.
   PubMed Web of Science ®Google Scholar
• Poltorak A, He X, Smirnova I, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 1998;282:2085–2088.
   PubMed Web of Science ®Google Scholar
• Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 2001;410:1099–1103.
   PubMed Web of Science ®Google Scholar
• Hemmi H, Takeuchi O, Kawai T, et al. A toll-like receptor recognizes bacterial DNA. Nature. 2000;408:740–745.
   PubMed Web of Science ®Google Scholar
• Kauppila JH, Mattila AE, Karttunen TJ, et al. Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue. Br J Cancer. 2013;108:638–643.
   PubMed Web of Science ®Google Scholar
• Zhou H, Chen JH, Hu J, et al. High expression of Toll-like receptor 5 correlates with better prognosis in non-small-cell lung cancer: an anti-tumor effect of TLR5 signaling in non-small cell lung cancer. J Cancer Res Clin Oncol. 2014;140:633–643.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest. 2007;117:823–834.
   PubMed Web of Science ®Google Scholar
• Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4:44–57.
   PubMed Web of Science ®Google Scholar
• Shatz M, Shats I, Menendez D, et al. p53 amplifies Toll-like receptor 5 response in human primary and cancer cells through interaction with multiple signal transduction pathways. Oncotarget. 2015;6:16963–16980.
   PubMedGoogle Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Shen JK, Cote GM, Choy E, et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014;2:690–698.
   PubMed Web of Science ®Google Scholar
• Marzec M, Zhang Q, Goradia A, et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci USA. 2008;105:20852–20857.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Feldman AL, Wada DA, et al. B7-H1 (PD-L1, CD274) suppresses host immunity in T-cell lymphoproliferative disorders. Blood. 2009;114:2149–2158.
   PubMed Web of Science ®Google Scholar
• Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol. 2004;4:499–511.
   PubMed Web of Science ®Google Scholar
• Vijay-Kumar M, Gewirtz AT. Flagellin: key target of mucosal innate immunity. Mucosal Immunol. 2009;2:197–205.
   PubMed Web of Science ®Google Scholar
• Rhee SH, Im E, Pothoulakis C. Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology. 2008;135:518–528.
   PubMed Web of Science ®Google Scholar
• Wang ZD, Qiao YL, Tian XF, et al. Toll-like receptor 5 agonism protects mice from radiation pneumonitis and pulmonary fibrosis. Asian Pac J Cancer Prev. 2012;13:4763–4767.
   PubMedGoogle Scholar
• Gooptu M, Rhoades R, Pro B. Current management of peripheral T-cell lymphomas. Cancer Treat Res. 2015;165:289–303.
   PubMedGoogle Scholar
• Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115:1026–1036.
   PubMed Web of Science ®Google Scholar
• Li MH, Fu SB, Xiao HS. Genome-wide analysis of microRNA and mRNA expression signatures in cancer. Acta Pharmacol Sin. 2015;36:1200–1211.
   PubMed Web of Science ®Google Scholar
• Guo L, Zhang Q, Ma X, et al. miRNA and mRNA expression analysis reveals potential sex-biased miRNA expression. Sci Rep. 2017;7:39812.
   PubMed Web of Science ®Google Scholar
• Ballester B, Ramuz O, Gisselbrecht C, et al. Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas. Oncogene. 2006;25:1560–1570.
   PubMed Web of Science ®Google Scholar
• Hong JY, Hong ME, Choi MK, et al. The clinical significance of activated p-AKT expression in peripheral T-cell lymphoma. Anticancer Res. 2015;35:2465–2474.
   PubMed Web of Science ®Google Scholar
• Ni X, Zhang X, Hu CH, et al. ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-kappaB pathways. Oncotarget. 2017;8:61761–61776.
   PubMedGoogle Scholar
• Menendez D, Shatz M, Azzam K, et al. The Toll-like receptor gene family is integrated into human DNA damage and p53 networks. PLoS Genet. 2011;7:e1001360.
   PubMed Web of Science ®Google Scholar
• Shatz M, Menendez D, Resnick MA. The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res. 2012;72:3948–3957.
   PubMed Web of Science ®Google Scholar
• Cai Z, Sanchez A, Shi Z, et al. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 2011;1;71:2466–2475.
   Web of Science ®Google Scholar
• Grimm M, Munz A, Exarchou A, et al. Immunohistochemical detection of Helicobacter pylori without association of TLR5 expression in oral squamous cell carcinoma. J Oral Pathol Med. 2014;43:35–44.
   PubMed Web of Science ®Google Scholar
• Flentie K, Gonzalez C, Kocher B, et al. Nucleoside diphosphate kinase-3 (NME3) enhances TLR5-induced NFkappaB activation. Mol Cancer Res. 2018;16:986–999.
   PubMed Web of Science ®Google Scholar